Trial Profile
Feasibility trial of UFT [tegafur/uracil] after withdrawal of adjuvant TS-1 [S 1] with adverse effects in patients with curatively resected gastric cancer
Status:
Suspended
Phase of Trial:
Phase II
Latest Information Update: 12 May 2016
Price :
$35
*
At a glance
- Drugs Tegafur/uracil (Primary)
- Indications Gastric cancer
- Focus Adverse reactions
- 30 Jan 2010 Status changed from recruiting to suspended as reported by University Hospital Medical Information Network - Japan.
- 29 May 2008 New trial record.